Why Vertex Pharmaceuticals Stock Is Jumping Today

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were jumping 8.2% as of 12:01 p.m. ET on Wednesday. The nice gain came after the big biotech announced positive results from a phase 2 proof-of-concept study evaluating VX-147 in treating patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS).

FSGS is a kidney disease caused by variants of the APOL1 gene. Individuals with FSGS can require dialysis or kidney transplants. Some eventually die of the disease, which currently has no approved therapies targeting the underlying cause.

Image source: Getty Images.

Continue reading

Source Fool.com